Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $16.26 billion. The enterprise value is $19.96 billion.
| Market Cap | 16.26B |
| Enterprise Value | 19.96B |
Important Dates
The next estimated earnings date is Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.62 million shares outstanding. The number of shares has decreased by -3.04% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.62M |
| Shares Change (YoY) | -3.04% |
| Shares Change (QoQ) | +1.68% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 60.65% |
| Float | 60.66M |
Valuation Ratios
The trailing PE ratio is 16.88 and the forward PE ratio is 20.37.
| PE Ratio | 16.88 |
| Forward PE | 20.37 |
| PS Ratio | 4.37 |
| Forward PS | 3.71 |
| PB Ratio | 2.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.15 |
| P/OCF Ratio | 13.71 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.47, with an EV/FCF ratio of 17.37.
| EV / Earnings | 20.72 |
| EV / Sales | 5.37 |
| EV / EBITDA | 15.47 |
| EV / EBIT | 15.97 |
| EV / FCF | 17.37 |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.93.
| Current Ratio | 2.02 |
| Quick Ratio | 2.01 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | 4.15 |
| Debt / FCF | 4.72 |
| Interest Coverage | 20.49 |
Financial Efficiency
Return on equity (ROE) is 17.53% and return on invested capital (ROIC) is 16.61%.
| Return on Equity (ROE) | 17.53% |
| Return on Assets (ROA) | 8.10% |
| Return on Invested Capital (ROIC) | 16.61% |
| Return on Capital Employed (ROCE) | 10.92% |
| Weighted Average Cost of Capital (WACC) | 6.47% |
| Revenue Per Employee | $1.25M |
| Profits Per Employee | $323,915 |
| Employee Count | 2,973 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 17.63 |
Taxes
In the past 12 months, Genmab has paid $241.00 million in taxes.
| Income Tax | 241.00M |
| Effective Tax Rate | 20.02% |
Stock Price Statistics
The stock price has increased by +30.11% in the last 52 weeks. The beta is 0.74, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | +30.11% |
| 50-Day Moving Average | 27.59 |
| 200-Day Moving Average | 28.71 |
| Relative Strength Index (RSI) | 43.02 |
| Average Volume (20 Days) | 1,578,547 |
Short Selling Information
The latest short interest is 7.93 million, so 1.31% of the outstanding shares have been sold short.
| Short Interest | 7.93M |
| Short Previous Month | 8.58M |
| Short % of Shares Out | 1.31% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.05 |
Income Statement
In the last 12 months, Genmab had revenue of $3.72 billion and earned $963.00 million in profits. Earnings per share was $15.37.
| Revenue | 3.72B |
| Gross Profit | 3.48B |
| Operating Income | 1.25B |
| Pretax Income | 1.20B |
| Net Income | 963.00M |
| EBITDA | 1.29B |
| EBIT | 1.25B |
| Earnings Per Share (EPS) | $15.37 |
Balance Sheet
The company has $1.72 billion in cash and $5.43 billion in debt, giving a net cash position of -$3.71 billion or -$60.22 per share.
| Cash & Cash Equivalents | 1.72B |
| Total Debt | 5.43B |
| Net Cash | -3.71B |
| Net Cash Per Share | -$60.22 |
| Equity (Book Value) | 5.85B |
| Book Value Per Share | 94.89 |
| Working Capital | 1.46B |
Cash Flow
In the last 12 months, operating cash flow was $1.19 billion and capital expenditures -$37.00 million, giving a free cash flow of $1.15 billion.
| Operating Cash Flow | 1.19B |
| Capital Expenditures | -37.00M |
| Depreciation & Amortization | 40.00M |
| Net Borrowing | 5.49B |
| Free Cash Flow | 1.15B |
| FCF Per Share | $18.65 |
Margins
Gross margin is 93.60%, with operating and profit margins of 33.60% and 25.89%.
| Gross Margin | 93.60% |
| Operating Margin | 33.60% |
| Pretax Margin | 32.37% |
| Profit Margin | 25.89% |
| EBITDA Margin | 34.68% |
| EBIT Margin | 33.60% |
| FCF Margin | 30.89% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.04% |
| Shareholder Yield | 3.04% |
| Earnings Yield | 5.92% |
| FCF Yield | 7.07% |
Analyst Forecast
The average price target for Genmab is $39.81, which is 48.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39.81 |
| Price Target Difference | 48.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 9.48% |
| EPS Growth Forecast (5Y) | 10.14% |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 2.48 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.48 |
| Piotroski F-Score | 4 |